Clinical Trials Browser

Phase 1/2 × INDUSTRY × margetuximab × Clear all

NCT02689284 2025-03-17

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Phase 1/2 Completed

95 enrolled 26 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms